FDA says biopsy needle too large for lumpectomy:
This article was originally published in Clinica
An FDA advisory panel said last week that there is no scientific evidence to suggest that two devices used for breast biopsies should also be marketed for lumpectomy. The two devices, US Surgical's ABBI and Biopsys Medical Mammotome, use larger needles than other biopsy devices, and thus take more tissue. In June, the FDA issued a warning letter to US Surgical to stop marketing its device for lumpectomy. The General and Plastic Surgery Devices panel also said the agency should restrict the product's use in breast biopsies in those cases that are difficult to diagnose.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.